Evaluation of the Organization of Continuity of Care for Home Hospice Patients by Four Parisian Health Networks (DICODOM)

In Paris, France, home hospice care for terminally ill patients is organized by four "palliative care networks". These networks are responsible for information sharing and coordination of all health care professionals working with the patient. Two different systems are in place to ensure continuity of care outside working hours, in such a setting. In the first system, palliative care specialists from the network are reachable over the phone 24/7 by the patient or its caregivers, whenever needed. In the second system, medical information about the patient, regularly updated by the network's medical team, is available to professionals via a secure website, so that in case the patient requires an urgent medical home visit outside working hours, the visiting physician has access to accurate information.

The study's goal is to compare patient's and caregiver's satisfaction between these two systems of continuity of care.

For that purpose, patients will be taken care of as usual by every palliative care network. In every instance where the patient or caregivers have reached out for medical help through the network's continuity of care system, the patient or caregiver will be called 5 days later by the investigation team to go through a satisfaction questionnaire (Likert scales)

Study Overview

• Status: Completed
• Conditions: Neoplasms; Neurodegenerative Diseases; Terminal Illness

• Study Type: Observational
• Enrollment (Actual): 200

Contacts and Locations

Study Locations

• France
  • Paris, France, 75003
    • Reseau QUIETUDE
  • Paris, France, 75012
    • Reseaux ROPE
  • Paris, France, 75013
    • Reseau ENSEMBLE
  • Paris, France, 75015
    • Reseaux ParisOuest

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

All patients newly followed for home hospice care by the four palliative care networks of Paris, France, during the inclusion period (up to the inclusion of 200 patients)

Description

Inclusion Criteria:

• Patient has a disease with fatal prognosis and requires palliative care
• Patient lives in Paris, France
• Patient benefits from home hospice care through one of the four official Paris palliative care networks

Exclusion Criteria:

• Pregnant women
• Breastfeeding womed
• Altered cognitive function with a Mini Mental Status below 20
• Patient not able to communicate or not speaking French
• Patient legally not capable of giving informed consent

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Satisfaction about the response given by the network's continuity of care system	Patient's (or caregiver's) satisfaction about the response given by the network's continuity of care system, after the patient or caregiver activated this system at night time or during week-ends or bank holliday, as measured on a 4-level Likert scale (verbal questionnaire by phone call)	between the first and tenth day after the patient or caregiver activated the network's continuity of care system

Collaborators and Investigators

• Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
• Investigators: Principal Investigator: Herve PICARD, MD MSc, Clinical Research Department, Rothschild Foundation, Paris (France)

Study record dates

Study Major Dates

• Study Start (Actual): March 29, 2017
• Primary Completion (Actual): June 20, 2018
• Study Completion (Actual): November 7, 2018

Study Registration Dates

• First Submitted: November 5, 2017
• First Submitted That Met QC Criteria: November 7, 2017
• First Posted (Actual): November 8, 2017

Study Record Updates

• Last Update Posted (Actual): December 7, 2018
• Last Update Submitted That Met QC Criteria: December 6, 2018
• Last Verified: November 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neurodegenerative Diseases
• Other Study ID Numbers: HPD_2016_24

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No